Before Submission, please refer to "Materials for Submission" and "Submit a Manuscript".

JDR Special Issue on COVID-19 and Historical Pandemics Part 2 (Vol.17 No.1, Jan. 2022)

Submission Deadline: October 15, 2021
Editors: 篠田純男(岡山大学名誉教授) Prof. Sumio Shinoda (Okayama University)
唐木英明(食の安心・安全財団) Dr. Hideaki Karaki (Foundation of Food Safety and Security)
林 春男(防災科学技術研究所) Dr. Haruo Hayashi (NIED)
More details: Dr17sp_CFP_COVID-19.pdf
Submit papers: e-mail to email
Inquiry: JDR Contact form or e-mail to email (JDR Editorial Office)

[in Japanese]
しかも、2021年の初め頃から、SARS-CoV-2のヒト細胞への侵入と発症に重要な働きをしているスパイク・タンパク質のN501Y, D614G, K417N, E484K, T716Iなどの変異株が南アフリカ、英国、インド等で発生して、わが国の感染者からも検出されて問題視されている。新たな変異株は、今後も発生することが予想されており、治療に支障を来す恐れがあり、既に接種が始められているワクチンの効果にも影響を与えかねない。
JDRでは、昨年このCOVID-19関連特集第1弾を組んで、本年1月に16報を載せた電子版として発行した(JDR Vol.16, No.1, pp.1-117)。しかし、未だ収束に至らない状態なので、この特集の第2弾を企画した。COVID-19による様々な医療問題、医療災害に関する問題と共に、経済、環境、教育、観光等の様々な問題に影響が及んでいるので、広い視野での論文の投稿を期待したい。

[in English]
COVID-19 was first identified in Wuhan, China at the end of 2019. Because the viral pathogen is similar to SARS-CoV, the pathogen of SARS which prevailed from 2002 to 2003, the International Committee on Taxonomy of Virus (ICTV) designated it SARS-CoV-2.
COVID-19 originated in China, but it became a pandemic around the Americas and Europe and is still spreading over one year after its outbreak.
Moreover, variants of the spike protein that plays an important role in the intrusion into human cells and the onset of SARS-CoV-2, such as N501Y, D614G, K417N, E484K, and T716I, have emerged in South Africa, England, India, and other countries since early in 2021. These variants have also been detected in patients of Japan, and it has become a social problem. New variants are expected to appear in the future, possibly hindering medical treatment and influencing the vaccination process, which has already begun.
Although there have been relatively fewer cases of infections in Japan than in Western countries, many carriers and patients have been reported in and around the metropolitan areas of Tokyo and Kyoto-Osaka-Kobe, and this infectious disease is spreading to the provinces. In April 2020, the Declaration of State of Emergency was issued and later lifted. However, as the third and fourth spikes in infections have come in succession, the Declaration of State of Emergency was issued again in the particular prefectures this year.
The rollout of vaccines has been slower in Japan than in Western countries, but the healthcare workers were vaccinated first, and the elderly have been inoculated since June this year.
The vaccines previously used in accordance with the Preventive Vaccination Act are classified into attenuated live vaccines, inactivated vaccines, component vaccines, toxoids, etc. and in this case of COVID-19 mRNA vaccine and viral vector vaccine are introduced. Both are a new type of vaccines that enable the cells of vaccinated persons to synthesize the protein of the viral antigen.
The JDR edited a Special Issue on COVID-19 Part 1 last year and published Volume 16 in an electronic version in January of this year (JDR Vol.16., No.1., pp. 1-117). Nonetheless, the COVID-19 situation has not yet returned to normal. Accordingly, we plan to publish Special Issue Part 2. We expect the submission of the papers with various healthcare issues and problems but also a variety of problems in terms of the economy, environment, education and education, travel and tourism, etc.

Before Submission, please refer to "Materials for Submission" and "Submit a Manuscript".

JDR Regular paper

Submit papers: e-mail to email
Inquiry: JDR Contact form or e-mail to email (JDR Editorial Office)

Regular paper submissions are always welcome!

*This site is desgined based on HTML5 and CSS3 for modern browsers, e.g. Chrome, Firefox, Safari, Edge, Opera.

Last updated on Oct. 20, 2021